COMPARISON OF THE POTENTIAL OF THE 2 EPIPODOPHYLLOTOXIN DERIVATIVES VP-16 AND VM-26 ON SMALL CELL-CANCER OF THE LUNG (SOCL) CELL-LINES

被引：0
|
作者：
ROED, H
VINDELOV, LL
CHRISTENSEN, IJ
HANSEN, HH
SPANGTHOMSEN, M
机构：
[1] FINSEN INST,DK-2100 COPENHAGEN O,DENMARK
[2] UNIV COPENHAGEN,INST PATHOL ANAT,DK-1168 COPENHAGEN K,DENMARK
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1985年 / 26卷 / MAR期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：334 / 334
页数：1
相关论文
共 50 条
  • [31] INTENSIVE INDUCTION CHEMOTHERAPY (IIC) OF SMALL CELL LUNG-CANCER (SCLC) WITH ECHO - E EPIPODOPHYLLOTOXIN VP-16, C CYTOXAN, H HYDROXYDAUNORUBICIN, O ONCOVIN
    VALDIVIESO, M
    CABANILLAS, F
    BEDIKIAN, AY
    MOUNTAIN, CF
    BARKLEY, HT
    BODEY, GP
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 383 - 383
  • [32] COMPARISON OF 2 METHODS FOR THE STUDY OF GROWTH AND DRUG SENSITIVITY OF SMALL CELL LUNG-CANCER CELL-LINES
    BICKNELL, S
    MILROY, R
    PLUMB, JA
    BANHAM, S
    KAYE, SB
    BRITISH JOURNAL OF CANCER, 1989, 60 (03) : 499 - 499
  • [33] ETOPOSIDE (VP-16) AND CYTOSINE-ARABINOSIDE IN THE TREATMENT OF RELAPSED SMALL-CELL LUNG-CANCER
    MARGOLIN, K
    AKMAN, S
    CARR, B
    LEONG, L
    DOROSHOW, J
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1988, 11 (04): : 499 - 501
  • [34] CISPLATINUM, VP-16, AND VINDESINE AS 2ND LINE THERAPY IN ACO REFRACTORY SMALL CELL LUNG-CANCER
    GATZEMEIER, U
    RADENBACH, D
    TUMORDIAGNOSTIK & THERAPIE, 1985, 6 (05) : 203 - 205
  • [35] 1ST-LINE THERAPY WITH VP-16 AND CISPLATIN FOR SMALL-CELL LUNG-CANCER
    EVANS, WK
    SHEPHERD, FA
    FELD, R
    OSOBA, D
    DEBOER, G
    SEMINARS IN ONCOLOGY, 1986, 13 (03) : 17 - 23
  • [36] THE USE OF VP-16 PLUS CISPLATIN DURING INDUCTION CHEMOTHERAPY FOR SMALL-CELL LUNG-CANCER
    EVANS, WK
    FELD, R
    MURRAY, N
    PATER, J
    SHELLEY, W
    WILLAN, A
    OSOBA, D
    LEVITT, M
    COY, P
    HODSON, I
    PAYNE, DG
    MACDONALD, AS
    SEMINARS IN ONCOLOGY, 1986, 13 (03) : 10 - 16
  • [37] EXPERIENCE WITH VP-16 COMBINED WITH CYCLOPHOSPHAMIDE OR ADRIAMYCIN IN ANAPLASTIC, PREDOMINANTLY SMALL-CELL LUNG-CANCER
    SCHMIEDER, HA
    JUNGI, WF
    MAYR, AC
    SENN, HJ
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1979, 109 (22) : 841 - 844
  • [38] ALTERNATING CHEMOTHERAPY WITH OR WITHOUT VP-16 IN EXTENSIVE-STAGE SMALL-CELL LUNG-CANCER
    EVERSON, LK
    JETT, JR
    OFALLON, JR
    KROOK, JE
    DALTON, RJ
    MAILLIARD, JA
    TSCHETTER, LK
    CULLINAN, SA
    GERSTNER, JB
    MORTON, RF
    LAURIE, JA
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1989, 12 (04): : 339 - 344
  • [39] VP-16 AND CISPLATIN AS 1ST-LINE THERAPY FOR SMALL-CELL LUNG-CANCER
    EVANS, WK
    SHEPHERD, FA
    FELD, R
    OSOBA, D
    DANG, P
    DEBOER, G
    JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (11) : 1471 - 1477
  • [40] MODULATION OF VP-16 INDUCED DNA-STRAND BREAKS IN HUMAN SMALL CELL LUNG-CANCER
    TRUCKSIS, M
    BERGER, NA
    CLINICAL RESEARCH, 1985, 33 (02): : A578 - A578
12345